| abstract |
The present invention relates to a novel use of leucine tRNA synthetase, and more particularly to a method for screening a test agent that inhibits the binding level of RagD to LRS, thereby screening for a preventive or therapeutic agent for mTORC1-mediated disease, And a method for reducing cell size relative to control cells. The method of the present invention provides a new method of adjusting the cell size, and the screening method can be usefully used for the development of a new therapeutic agent for diseases such as cancer. |